Tetanus - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Tetanus - Pipeline Review, H2 2016

Tetanus - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Tetanus - Pipeline Review, H2 2016
Published Sep 21, 2016
100 pages — Published Sep 21, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tetanus - Pipeline Review, H2 2016, provides an overview of the Tetanus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tetanus
- The report reviews pipeline therapeutics for Tetanus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Tetanus therapeutics and enlists all their major and minor projects
- The report assesses Tetanus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Tetanus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Tetanus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective

  
Source:
Document ID
GMDHC8482IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Tetanus Overview101
Therapeutics Development112
  Pipeline Products for Tetanus Overview111
  Pipeline Products for Tetanus Comparative Analysis121
Tetanus Therapeutics under Development by Companies132
Tetanus Therapeutics under Investigation by Universities/Institutes151
Tetanus Pipeline Products Glance163
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
Tetanus Products under Development by Companies192
Tetanus Products under Investigation by Universities/Institutes211
Tetanus Companies Involved in Therapeutics Development2217
  Beijing Minhai Biotechnology Co., Ltd221
  Bharat Biotech International Limited231
  BioClonetics Immunotherapeutics, Inc.241
  Biological E. Limited251
  Boryung Pharmaceutical Co., Ltd.261
  Daiichi Sankyo Company, Limited271
  GlaxoSmithKline Plc281
  Green Cross Corporation291
  Indian Immunologicals Limited301
  Kaketsuken K.K.311
  LG Life Science LTD.321
  Panacea Biotec Limited331
  Prometheon Pharma, LLC341
  Sanofi Pasteur SA351
  Serum Institute of India Limited361
  Sinovac Biotech Ltd.371
  Zydus Cadila Healthcare Limited381
Tetanus Therapeutics Assessment398
  Assessment by Monotherapy Products391
  Assessment by Combination Products401
  Assessment by Target412
  Assessment by Route of Administration432
  Assessment by Molecule Type452
Drug Profiles4739
  (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine Drug Profile471
  (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine Drug Profile481
  (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine Drug Profile491
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine Drug Profile501
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine Drug Profile511
  (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine Drug Profile521
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile531
  (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile541
  (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine Drug Profile551
  (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine Drug Profile561
  (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine Drug Profile571
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile581
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile591
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile601
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile611
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile621
  (diphtheria + pertussis (acellular) + tetanus) vaccine 1 Drug Profile631
  (diphtheria + pertussis (acellular) + tetanus) vaccine 2 Drug Profile641
  (diphtheria + pertussis (whole cell) + tetanus) vaccine Drug Profile651
  (diphtheria + pertussis (whole-cell) + tetanus) vaccine Drug Profile661
  (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine Drug Profile672
  (diphtheria + tetanus + pertussis (acellular)) vaccine Drug Profile691
  (diphtheria + tetanus) vaccine Drug Profile701
  diphtheria + pertussis(acellular) + tetanus vaccine Drug Profile711
  Eupenta Drug Profile721
  GC-1107 Drug Profile731
  GC-3111A Drug Profile741
  KD-370 Drug Profile751
  LBVD Drug Profile761
  Monoclonal Antibody for Tetanus Drug Profile771
  Monoclonal Antibody for Tetanus Drug Profile781
  Monoclonal Antibody to Target Tetanus Toxin for Tetanus Drug Profile791
  tetanus vaccine Drug Profile801
  tetanus vaccine Drug Profile811
  tetanus vaccine Drug Profile821
  tetanus vaccine Drug Profile831
  VN-0103 Drug Profile841
  VN-0105 Drug Profile851
Tetanus Dormant Projects862
Tetanus Discontinued Products881
Tetanus Product Development Milestones8910
  Featured News &Press Releases891
    Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta891
    Nov 24, 2014: CanSinotech submitted CTA of Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed to CFDA891
    Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur s Investigational Pediatric Hexavalent Vaccine891
    Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age901
    Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima911
    Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine921
    Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets921
    Jun 22, 2012: Sanofi Pasteur s Hexaxim Receives Positive Opinion From European Medicines Agency931
    Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series941
    Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis951
    Jun 13, 2005: U.S. FDA Licenses sanofi Pasteur s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis951
    Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine961
    Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis961
    Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.971
    May 14, 2002: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children981
Appendix992
  Methodology991
  Coverage991
  Secondary Research991
  Primary Research991
  Expert Panel Validation991
  Contact Us991
  Disclaimer1001

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tetanus - Pipeline Review, H2 2016" Sep 21, 2016. Alacra Store. May 07, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tetanus-Pipeline-Review-H2-2016-2088-16579>
  
APA:
Global Markets Direct - Market Research. (2016). Tetanus - Pipeline Review, H2 2016 Sep 21, 2016. New York, NY: Alacra Store. Retrieved May 07, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tetanus-Pipeline-Review-H2-2016-2088-16579>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.